Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Vascular Dysfunction in Offspring of Assisted Reproduction Technologies

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2009 by University of Lausanne Hospitals.
Recruitment status was:  Recruiting
Sponsor:
Information provided by:
University of Lausanne Hospitals
ClinicalTrials.gov Identifier:
NCT00837642
First received: February 4, 2009
Last updated: NA
Last verified: January 2009
History: No changes posted
  Purpose

The prevalence of infertility has been estimated at 9% worldwide. The steadily increasing use of assisted reproductive technologies (ART) has allowed millions of infertile couples to have children. These children make up for 1 to 4% of the population in developed countries. ART involves the manipulation of early embryos at a time when they may be particularly vulnerable to external disturbances. In line with this concept, studies in mice suggest that ART alters the activity of enzymes involved in the regulation of metabolic and cardiovascular homeostasis. Alternatively, infertility itself or the drugs used to stimulate ovulation may have adverse effects on the outcome of the offspring. The safety of ART for long-term health is, therefore, of utmost importance. Among the potential long-term consequences of ART, cardiovascular disease may represent an important candidate, but there is no information.

Preliminary data from our group show that, children born after in vitro fertilization (IVF) present systemic and pulmonary vascular dysfunction at high-altitude when compared to age- and sex-matched control subjects.

Therefore, the major goal of our proposal is to test the hypothesis that apparently healthy children born after ART display vascular dysfunction of both the pulmonary and the systemic circulation.


Condition Intervention
Infertility
Dietary Supplement: Vitamin C and E

Study Type: Interventional
Official Title: Vascular Dysfunction in Offspring of Assisted Reproduction Technologies

Resource links provided by NLM:


Further study details as provided by University of Lausanne Hospitals:

Primary Outcome Measures:
  • Endothelial function [ Designated as safety issue: No ]

Study Start Date: March 2008
Estimated Study Completion Date: December 2009
Estimated Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   10 Years to 18 Years   (Child, Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Offspring of ART
  • Healthy
  • No medication
  • Born at term

Exclusion Criteria:

  • Cardio-pulmonary malformations
  • Neuro-muscular malformations
  • Previous high altitude diseases
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00837642

Locations
Switzerland
University Hospital
Bern, BE, Switzerland, 3000
University Hospital
Lausanne, VD, Switzerland, 1011
Sponsors and Collaborators
University of Lausanne Hospitals
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Prof Urs Scherrer, University Hospital Lausanne
ClinicalTrials.gov Identifier: NCT00837642     History of Changes
Other Study ID Numbers: 35/07 
Study First Received: February 4, 2009
Last Updated: February 4, 2009
Health Authority: Switzerland: Federal Office of Public Health

Keywords provided by University of Lausanne Hospitals:
Vascular function in offspring of ART

Additional relevant MeSH terms:
Infertility
Genital Diseases, Male
Genital Diseases, Female

ClinicalTrials.gov processed this record on December 09, 2016